Strategic Expansion MindMaze has global offices and ongoing leadership changes with a new CEO appointed in 2026, signaling an expansion phase and potential cross-border sales opportunities, especially in the USA where adoption of FDA-cleared neurorestorative platforms is being pursued.

FDA Cleared Platform Leveraging FDA clearance and CE marking, MindMaze offers neuro-digital therapeutics that can be positioned to health systems, rehabilitation centers, and payers seeking evidence-backed digital interventions for stroke, Alzheimer’s, and Parkinson’s recovery.

Strategic Partnerships Past collaborations with Virta Health and high-profile financing indicate openness to integration and co-development with healthcare providers and digital health ecosystems, presenting opportunities for bundled solutions and joint go-to-market efforts.

Capital and Scale Significant funding and private equity activity, including a recent financing round and private merger activity, suggest capacity for large-scale deployments and discounted pilots with health networks seeking proven digital neurorehabilitation.

Rehabilitation Focus The MindMotion GO platform and neurorehabilitation emphasis position MindMaze to target hospital networks, rehabilitation clinics, and long-term care facilities seeking scalable digital therapies to accelerate neurological recovery and reduce inpatient burden.